Seeking Alpha

Cell Therapeutics (CTIC +15.2%) jumps after announcing the licensing terms under which Novartis...

Cell Therapeutics (CTIC +15.2%) jumps after announcing the licensing terms under which Novartis (NVS) would be able to develop and commercialize CTIC's Pixuvri cancer drug, which was recently approved by the EU. Should Novartis exercise its option on Pixuvri, the drug giant would owe CTIC a $7.5M license fee, up to $104M in milestone payments, and ongoing royalties.
From other sites
Comments (3)
  • paulwilliam
    , contributor
    Comments (6) | Send Message
     
    I hope that CTIC can avoid any Dendreon fiascos.
    27 Aug 2012, 01:13 PM Reply Like
  • Mr. Huffington
    , contributor
    Comments (5) | Send Message
     
    Until conditional marketing authorization is lifted, Novartis will remain on the sidelines.
    27 Aug 2012, 04:24 PM Reply Like
  • grateful908
    , contributor
    Comments (110) | Send Message
     
    How much you wanna bet CTIC dilutes the share price with another 85 billion( being sarcastic) cheap shares??? This Co. has to make approx. one BILLION dollars for it's shares to actually be worth anything !!!!! RUN, RUN, from this company !!!!!
    27 Aug 2012, 10:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs